1. Nanopharmaceutics in immunology: what's new in research?
Ranjita Shegokar, Ana Rita Fernandes and Eliana Souto
2. Skin delivery of antimicrobial peptides
Monika Schaefer-Korting and Jens Rolff
3. Skin penetration of nanoparticles
Shohreh Nafisi and Howard I. Maibach
4. Regulatory and risk assessment perspective for Core-Multishell Nanocarriers: A novel excipient on its way towards marketing authorization
Sam D. More, Margret More, Florian Paulus, Emanuel Fleige amd Marcin Libera
5. Anti-inflammatory drugs: Pharmaceutical Nanotechnology approach
Andjelka B. Kovačevic, Sergio M.C.Silva and Slavomira Doktorovova
6. New strategies for the treatment of auto-immune diseases using nanotechnologies
Amelia M. Silva, Joao R. Siopa, Carlos Martins-Gomes, Maria C. Teixeira, Dario J. Santos, Maria dos Anjos Pires and Tatiana Andreani
7. Nanopharmaceutics Applications in Inhaler Systems
Aysu Yurdasiper, Mesut Arici and Mine Ozyazici
8. Immunomodulatory Effects of Curcumin in infectious and non-infectious diseases
9. Advances in Antibiotic Nanotherapy: Overcoming Antimicrobial Resistance
Teixeira, M.C., Sanchez-Lopez, E., Espina, M., Calpena, A.C., Silva, A.M., Veiga, F.J., Garcia, M. L., Souto, E.B.
Emerging Nanotechnologies in Immunology aims to deliver a systematic and comprehensive review of data concerning the nature of interaction and nano-related risks between the nanophamaceuticals currently in the pipeline of S&T development for skin, ocular, and nasal drug delivery, including absorption, toxicity, and the ability to distribute after systemic exposure.
The scientific development of manufactured nanomaterials for drug delivery is increasing rapidly. One of the most prominent applications is topical drug delivery, where cutaneous, ocular, and nasal exposure becomes even more relevant. These targets are the first barrier that nanoparticles encounter when in contact with the human body.
The contributors addresses a representative set of the broad spectrum of nanopharmaceuticals currently being used, including cationic lipid nanoparticles, polymeric PLGA, PLA nanoparticles, biomacromolecules-based nanoparticles, and other scaffolds tissue engineered skin substitutes. Regulation and risk is also covered, since the safety of these nanophamaceuticals still represents a barrier to their wide innovative use.
- Provides the reader with a thorough knowledge of the safety aspects of nanopharmaceuticals which are currently under research
- Focuses on the characterization and quantification of the nanopharmaceuticals
- Allows readers to understand the correlation between the nature of the materials and their potential nanotoxicological effects.
- Includes an overview of regulatory aspects related to the R&D of nanopharmaceuticals.
Academics, researchers and scientists, as well as post-graduates, developing their research in the area of Topical Drug Delivery; Policy makers and pharmaceutical companies and learned societies, associations and research groups working in topical nanopharmaceuticals
- No. of pages:
- © Elsevier 2018
- 19th May 2018
- Hardcover ISBN:
- eBook ISBN:
Dr. Ranjita Shegokar holds a PhD degree in Pharmaceutical Technology from the SNDT University, India, and has been postdoctoral researcher in the Department of Pharmaceutics, Biopharmaceutics and NutriCosmetics at Free University of Berlin, Germany. Since last 7 years she is working in the pharmaceutical industry in various technical/R&D roles. Currently, she serves as Head of Formulation Development Department at Symrise AG, Germany. She has authored more than 45 research articles, 20 book chapters, and 150 research abstracts. She has filed two patent applications on nanoparticles for targeting malaria and HIV/AIDS reservoirs and have 12 other patent application in area of active delivery. She is a recipient of several national and international awards for her research. Her areas of interest are oral solid dosage forms, dermal formulations, nanocrystals, lipid nanoparticles (SLNs/NLCs), nanoemulsions, and galenic formulations.
Head, Formulation Development Department, Symrise AG, Germany
Prof. Eliana B. Souto is affiliated with the Department of Pharmaceutical Technology of the Faculty of Pharmacy, University of Coimbra, Portugal. She is graduated in Pharmaceutical Sciences from the same University (2000). She holds a master’s degree in Pharmaceutical Technology and Pharmacotechnique from the Faculty of Pharmacy, University of Porto, Portugal (2002) and a PhD in Pharmaceutical Technology, Biopharmaceutics, and Biotechnology from the Institut fuer Pharmazie der Freie Universitaet Berlin, Germany (2005). Since August 2012, she has held the habilitation degree (Dr. Habil.) from the University Fernando Pessoa, Portugal. Her research lines focus on the design, development, and characterization of new drug delivery systems. Other research interests include the controlled delivery of drugs across biological barriers, with especial emphasis for ocular and skin administration.
Department of Pharmaceutical Technology of the Faculty of Pharmacy, University of Coimbra, Portugal.